Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Advancing Standards of Care in Pediatric Rheumatology
-
- 5 Top Stories About Gout
- Amgen Receives FDA Response Letter for Evenity
- FDA Advisory Committee Recommends Approval of Xeljanz for PsA
- FDA Advisory Committee Rejects Approval for Sirukumab, Voices Safety Concerns
- FDA Approves Orencia for PsA
- FDA Approves Self-injectable Formulation of Benlysta for Lupus
- Renflexis, a Biosimilar to Remicade, Launched in the US
- IgG4 Disease and Zen: Is There Another Association? Leonard H. Calabrese, DO
-
- Exploring the Mysteries of IgG4-related Disease
- Pharmacy Benefit Managers: Drug Industry’s Hidden Middlemen Ally Lopshire, JD
- Remission, Personalization Are Key in 2017 SpA, PsA Treatments to Target Update
- Study: Anti-CD20 Agent Treatment Can Be Guided by B-cell Monitoring for Lupus
- Allopurinol Linked With Reduced Risk of Renal Disease Compared With Febuxostat
- Arthritis, Chronic Conditions Associated With Lower Health-related Quality of Life
- Insurance Type Linked With Biologic Treatment for Patients With RA
- Low Market Competition Causes High Generic Drug Prices
-
- Rheumatologist Advocates for Health Care Equality
- Methotrexate Underuse: ‘Missed Opportunity’ for Value-based Care
- ACR Responds to 2018 Medicare Proposed Rule
- Baricitinib Treatment Yielded Similar Infection Risk as Other Therapies for RA
- FDA Aims to Increase Transparency, Improve Efficiency of Approval System
- Speakers: Lupus Remains Challenging Disease
- Tofacitinib Plus MTX Found Noninferior to Adalimumab Plus MTX